Research progress of DNA methylation in the diagnosis and treatment of thyroid carcinoma

IF 4.8 2区医学 Q2 IMMUNOLOGY

International immunopharmacology Pub Date : 2025-03-09 DOI:10.1016/j.intimp.2025.114426

Xin Zhang , Bing Luo , Minjie Sun , Deyu Gao , Sufang Xu

引用次数: 0

Abstract

Thyroid cancer is the most prevalent endocrine malignancy, and its timely and accurate diagnostic and prognostic assessments are crucial for enhancing patient survival rates. As an important epigenetic modification, DNA methylation plays a key role in the regulation of gene expression and tumorigenesis. Recent studies increasingly indicate that abnormal DNA methylation patterns are closely associated with the onset and progression of thyroid cancer. This review discusses the role of DNA methylation in diagnosing thyroid adenocarcinoma, its impact on prognosis, and its potential utility in cancer immunotherapy. Additionally, it explores the prospect of using DNA methylation as a biomarker and highlights its significant potential in the personalized treatment of thyroid cancer. This article aims to serve as a resource for future research and clinical applications to advance the diagnosis and treatment of thyroid cancer.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

International immunopharmacology 医学-免疫学

CiteScore

8.40

自引率

3.60%

发文量

935

审稿时长

53 days

期刊介绍： International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.